

type of report	Current report
number	6/2015
company	PHARMENA

Current Report No. 6/2015

The Management Board of Pharmena S.A. presents the January 2015 monthly report.

1. Information on trends and events occurring in the Issuer's market environment

To the best knowledge of the Management Board, no trends or events, which could significantly influence financial results of the company, occurred in January 2014 in the Issuer's market environment.

In January 2014, Pharmena accomplished sales revenue from its dermatological cosmetics in the amount reaching 865 thousand PLN. Obtained revenue was nearly 3% higher than the revenue achieved in an analogical period of the previous year.

In the said period, Pharmena S.A. enhanced the availability of its products and performed marketing actions in order to increase sales profit from marketed products.

In the area of works concerning 1-MNA innovative anti-atherosclerosis medicinal product, the following events occurred during the period covered by this report:

1) In relation to the Strategy of the Company for the years 2012-2015 (published in the current report No. 16/2012 dated 13.04.2012), as well as notification on the progress of clinical tests concerning 1-MNA innovative anti-atherosclerosis medicinal product (published in the current report No. 56/2014 dated 06.11.2014) the Management Board of PHARMENA S.A. informed that on 19 December 2014 29 patients have been enrolled into the II phase clinical trial of 1-MNA anti-atherosclerosis medicinal product, including 10 patients who completed the trial.

2) With reference to the information on obtaining permission for a change in the report on clinical trials on 1-MNA innovative anti-atherosclerosis medicinal product (published in current report No. 61/2014 of 01.12.2014) the Management Board of PHARMENA S.A. informs that according to the status reported on 20 January 2015, 11 clinics, participating in phase II clinical trials ("Proof of Concept") on innovative anti-atherosclerosis medicinal product based on the 1-MNA active substance, obtained permissions from Ethical Committees to introduce a change in the report on clinical trials within the scope of the selection criteria regarding HDL-c cholesterol. Health Canada approved this change on 28 November 2014 and the Issuer informed about this fact in current report No. 61/2014 of 01.12.2014. Remaining Clinics submitted all required documents to Ethical Committees and they expect the issuance of appropriate permissions. As far as all 11 clinics that obtained permissions to conduct clinical trials according to changed criteria are concerned, only 2 of them shall begin enrolment based on new principles in January this year, whereas 9 remaining clinics shall begin enrolment based on new principles on 5 February this year.

The aim of phase II clinical trial on the 1-MNA anti-atherosclerosis medicinal product is to establish the effective dose of the medicinal product and to confirm the lack of side effects in humans in the tested doses. The Montreal Heart Institute is the institution supervising the trial.

The Montreal Heart Institute is a leading research centre in Canada, specialising in cardiology, and one of the largest institutes of this type in the world. It is a world-renowned institute that has introduced many innovatory solutions nationally and worldwide. For more information see www.icm-mhi.org.

Phase II clinical trials ("Proof of Concept") are financed from funds raised in the issue of series D shares.

Moreover in January 2015, the Issuer's Capital Group continued its research and development work on new products and searched for new applications for active substances protected by patents and patent applications owned by the Issuer's Capital Group.

2. Achievement concerning the goals of an issue

In January 2015, Pharmena S.A. did not make any money expenditure directly on issue-related purposes. However, in the reported period, a subsidiary company Cortria Corporation spent its funds mainly to cover the costs of its operating activities.

3. List of all reports published by the Issuer between 01.01.2015 and 31.01.2015

During the period covered by this report, Pharmena S.A. published the following reports in EBI system:

- Current Report No. 1/2015 of 08-01-2015 – Information on the progress of clinical trials on 1-MNA innovative anti-atherosclerosis medicinal product
- Current Report No. 2/2015 of 12-01-2015 – Dates of publishing periodic reports in the year 2015
- Current Report No. 3/2015 of 14-01-2015 – December 2014 monthly report
- Current Report No. 4/2015 of 21-01-2015 – Information on the progress in clinical trials on innovative anti-atherosclerosis medicinal product 1-MNA

During the period covered by this report, Pharmena S.A. did not publish any reports in ESPI system.

4. Investor's calendar for February 2015.

13.02.2015 – publication of report for the IV quarter of the year 2014

Until 14.03.2015 - publication of February 2015 monthly report

Legal basis: Resolution No. 795/2008 of the Warsaw Stock Exchange Management Board dated 31st November 2008 concerning the adoption of the codes of best practice applicable on the NewConnect market, Appendix 1, point 16.